Ordering Recommendation

Determine BRAF V600E mutation status in patients with solid tumors to select candidates for targeted therapy with kinase inhibitors (BRAF and/or MEK). Monitor response to therapy and disease progression in patients carrying BRAF V600E mutation.

Mnemonic
BRAF CFDNA
Methodology

Polymerase Chain Reaction

Performed

Varies

Reported

9-12 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Whole blood in two 10mL Cell-Free DNA (cfDNA) BCT Tubes. Specimens must be collected using the Kit, Cell-Free DNA Blood Collection Tube (ARUP Supply #52358) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787.

Specimen Preparation

Transport 20 mL whole blood in cfDNA BCT Tubes. (Min: 16 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

FFPE tissue. Whole blood collected in non-cfDNA BCT tubes.

Remarks
Stability

Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable

Reference Interval

Refer to report.

Interpretive Data



Compliance Category

Laboratory Developed Test (LDT)

Note
Hotline History
N/A
CPT Codes

81210

Components
Component Test Code* Component Chart Name LOINC
2013922 BRAF V600E cfDNA Result 58415-1
2013924 BRAF V600E cfDNA Mutant Allele Frequency
2013925 BRAF V600E cfDNA Mutant copies/mL
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
BRAF V600E Mutation Detection in Circulating Cell-Free DNA by Digital Droplet PCR